Severe clinical outcomes of COVID-19 associated with proton pump inhibitors : a nationwide cohort study with propensity score matching
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: The adverse effects of proton pump inhibitors (PPIs) have been documented for pneumonia; however, there is no consensus regarding whether the use of PPIs might be harmful regarding the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this regard, we aimed to measure the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing.
DESIGN: Data were derived from a Korean nationwide cohort study with propensity score matching. We included 132 316 patients older than 18 years who tested for SARS-CoV-2 between 1 January and 15 May 2020. Endpoints were SARS-CoV-2 positivity (primary) and severe clinical outcomes of COVID-19 (secondary: admission to intensive care unit, administration of invasive ventilation or death).
RESULTS: In the entire cohort, there were 111 911 non-users, 14 163 current PPI users and 6242 past PPI users. After propensity score matching, the SARS-CoV-2 test positivity rate was not associated with the current or past use of PPIs. Among patients with confirmed COVID-19, the current use of PPIs conferred a 79% greater risk of severe clinical outcomes of COVID-19, while the relationship with the past use of PPIs remained insignificant. Current PPI use starting within the previous 30 days was associated with a 90% increased risk of severe clinical outcomes of COVID-19.
CONCLUSION: Patients taking PPIs are at increased risk for severe clinical outcomes of COVID-19 but not susceptible to SARS-CoV-2 infection. This suggests that physicians need to assess benefit-risk assessments in the management of acid-related diseases amid the COVID-19 pandemic.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Gut - 70(2021), 1 vom: 01. Jan., Seite 76-84 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Seung Won [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epidemiology |
|---|
| Anmerkungen: |
Date Completed 28.12.2020 Date Revised 30.03.2023 published: Print-Electronic CommentIn: Gut. 2021 Sep;70(9):1802-1803. - PMID 33077573 Citation Status MEDLINE |
|---|
| doi: |
10.1136/gutjnl-2020-322248 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313079153 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313079153 | ||
| 003 | DE-627 | ||
| 005 | 20231225145810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/gutjnl-2020-322248 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313079153 | ||
| 035 | |a (NLM)32732368 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Seung Won |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe clinical outcomes of COVID-19 associated with proton pump inhibitors |b a nationwide cohort study with propensity score matching |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.12.2020 | ||
| 500 | |a Date Revised 30.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Gut. 2021 Sep;70(9):1802-1803. - PMID 33077573 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: The adverse effects of proton pump inhibitors (PPIs) have been documented for pneumonia; however, there is no consensus regarding whether the use of PPIs might be harmful regarding the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this regard, we aimed to measure the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing | ||
| 520 | |a DESIGN: Data were derived from a Korean nationwide cohort study with propensity score matching. We included 132 316 patients older than 18 years who tested for SARS-CoV-2 between 1 January and 15 May 2020. Endpoints were SARS-CoV-2 positivity (primary) and severe clinical outcomes of COVID-19 (secondary: admission to intensive care unit, administration of invasive ventilation or death) | ||
| 520 | |a RESULTS: In the entire cohort, there were 111 911 non-users, 14 163 current PPI users and 6242 past PPI users. After propensity score matching, the SARS-CoV-2 test positivity rate was not associated with the current or past use of PPIs. Among patients with confirmed COVID-19, the current use of PPIs conferred a 79% greater risk of severe clinical outcomes of COVID-19, while the relationship with the past use of PPIs remained insignificant. Current PPI use starting within the previous 30 days was associated with a 90% increased risk of severe clinical outcomes of COVID-19 | ||
| 520 | |a CONCLUSION: Patients taking PPIs are at increased risk for severe clinical outcomes of COVID-19 but not susceptible to SARS-CoV-2 infection. This suggests that physicians need to assess benefit-risk assessments in the management of acid-related diseases amid the COVID-19 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a proton pump inhibition | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 700 | 1 | |a Ha, Eun Kyo |e verfasserin |4 aut | |
| 700 | 1 | |a Yeniova, Abdullah Özgür |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Sung Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, So Young |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Hyun Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jee Myung |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Su Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Sun Joon |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Joo Young |e verfasserin |4 aut | |
| 700 | 1 | |a Yoo, In Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Yon, Dong Keon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gut |d 1960 |g 70(2021), 1 vom: 01. Jan., Seite 76-84 |w (DE-627)NLM000003557 |x 1468-3288 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:76-84 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/gutjnl-2020-322248 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2021 |e 1 |b 01 |c 01 |h 76-84 | ||